BioWorld

June 27, 2007

View Archived Issues

Genentech, Abbott Partner To Develop Oncology Drugs

Genentech Inc. is acting the pharma part in a deal with Abbott to advance the latter's Phase I-stage compounds ABT-263 and ABT-869, a Bcl-2 protein antagonist and VEGF receptor kinase inhibitor, respectively. (BioWorld Today) Read More

MediciNova Picks 2 Programs, Looks To Partner Most Others

Read More

Broader Comparison Finds More Specific Angiogenesis Markers

Read More

NewCo News: Cequent's RNAi Platform Draws Novartis Investment, Option

Read More

Generex Gears Up For Phase III Trial Of Oral-lyn Insulin Spray

Read More

Clinic Roundup

Read More

Other News To Note

Read More